Decades of Progress in Allogeneic Stem Cell Transplantation for Multiple Myeloma
Hemato · 2021
DOI: 10.3390/hemato2010005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hemato, 2021. Verfasst von Benedetto Bruno und 3 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Allogeneic hematopoietic cell transplantation in multiple myeloma has evolved over the decades. Myeloablative regimens have been replaced by the reduced intensity and non-myeloablative conditionings to reduce treatment-related toxicity and mortality while sparing graft-vs.-myeloma effects. Newer agents with potent anti-myeloma activity are not mutually exclusive and the combination with an allograft may improve long-term outcomes in this incurable disease especially in high-risk patients. Allografting may also be a platform for other promising new cell therapies such as CAR T-cells, NK-, and CAR NK-cells. These studies are warranted in the context of clinical trials. This review highlights the progress that has been made over the decades and possible future roles of allografting in the treatment landscape of multiple myeloma
Zitieren
APA
Bruno, B., Lia, G., Bonifazi, F., & Giaccone, L. (2021). Decades of Progress in Allogeneic Stem Cell Transplantation for Multiple Myeloma. Hemato. https://doi.org/10.3390/hemato2010005
Vancouver
Bruno B, Lia G, Bonifazi F, Giaccone L. Decades of Progress in Allogeneic Stem Cell Transplantation for Multiple Myeloma. Hemato. 2021. doi:10.3390/hemato2010005
BibTeX
@article{Bruno2021,
author = {Bruno, Benedetto and Lia, Giuseppe and Bonifazi, Francesca and Giaccone, Luisa},
title = {Decades of Progress in Allogeneic Stem Cell Transplantation for Multiple Myeloma},
journal = {Hemato},
year = {2021},
doi = {10.3390/hemato2010005}
}
EUVIMED